Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com

Jefferies cut its price target on Mineralys (MLYS) to $30 from $42 and kept a Hold, citing weak differentiation of lorundrostat versus baxdrostat and saying consensus 2030 revenue estimates of $1.2–$1.4B look too high. Countering that, BofA raised its PT to $51 (Buy) and Stifel reiterated Buy with a $52 target; shares trade near $26.30. Mineralys reported Q4 2025 EPS of -$0.40 vs consensus -$0.94 (positive surprise) but faces higher G&A and mixed trial results. The FDA accepted the NDA with a PDUFA date of Dec 22, 2026, leaving commercialization strategy (M&A, partnership, or independent launch) undecided.

Analysis

If the entrant lacks clear clinical differentiation versus incumbents, the commercial market will shift from a clinical-value debate to a price-and-formulary fight — that materially compresses peak revenue assumptions because payers prioritize lowest net-cost and established safety profiles when clinical advantage is marginal. Expect initial uptake to be concentrated in narrow specialty clinics and KOL-driven centers; broad primary-care adoption — where volume lives — will require either demonstrable real-world superiority or aggressive net pricing, both of which are expensive and slow to achieve.

Commercial readiness is a two-edged sword: investing to win formulary placement (field force, payer-account teams, REMS support) inflates burn and extends the cash runway breakeven window by 18–36 months absent rapid uptake. That amplifies M&A optionality — a partner with an existing sales infrastructure can compress commercialization cost by 30–50% versus independent launch — but it also caps acquisition prices because buyers will price in label restrictions and expected payer discounts.

The regulatory/market path is binary in the near term but path-dependent thereafter: a favorable regulatory posture without a differentiating label still leaves the company exposed to pricing pressure and slower-than-expected adoption, while a clearly superior outcome in a defined subgroup can re-open upside and materially raise takeover valuations. That makes event-driven option structures and hedged equity the most efficient ways to express a view while controlling downside.

Key Decisions for Investors

• Event-driven long (MLYS equity + hedge): Buy MLYS up to 3% of strategy size, size to a stop-loss at -30% from entry; simultaneously buy 6–12 month protective puts (5–10% OTM) to cap downside. Rationale: asymmetric payoff if a commercial partner deal or positive label clarity emerges within 6–12 months; risk limited by put cost, reward 2–4x on takeover/strong uptake scenario.
• Defined-risk options spread: Buy a 9–12 month MLYS call spread (buy lower strike / sell higher strike) sized to 1–2% of fund NAV. This captures upside from favorable commercial/mktshare reads while capping premium outlay; target 150–300% return if market re-rates post-catalyst, max loss = premium paid.
• Cash-secured short or put-buy for skeptics: If conviction is that launch economics will be weak, sell covered call against a partial short position or buy deep OTM puts with 6–9 month expiries to profit from downside while keeping capital efficient. Risk: regulatory or M&A upside can spike implied vols; cap exposure to 1% of NAV.
• Relative-value pair: Long MLYS (smaller size) / short a small-cap biotech basket or sector ETF (e.g., IBB) to isolate idiosyncratic allocation to commercialization execution vs sector beta. Timeframe 6–18 months; aim for 1.5:1 gross exposure, reduce sector noise and focus on company-specific catalysts.
• Liquidity and staging rule: Do not commit >50% of intended position pre-catalyst. Stage entries in two tranches (now and post-first commercial/payer read) to manage information asymmetry and avoid overpaying before real-world utilization signals — this reduces probability of large drawdowns from adverse early uptake signals.